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CC BY-NC-ND license (http://creativeAbstract Radical cystectomy has remained the gold standard for recurrent superficial or
muscle invasive bladder tumor. However, partial cystectomy still has a role in those who reject
or have contraindications for radical cystectomy. In this study, we sought to identify predictors
of bladder recurrence and overall survival after simple partial cystectomy. We included 27 pa-
tients with bladder tumor who received simple partial cystectomy without pelvic lymph node
dissection between March 2000 and September 2013. Adjuvant chemotherapy or radiation
therapy was prescribed according to the pathological results. Parameters were compared on
the basis of bladder recurrence and overall survival. During a mean follow-up time of
39 months, five patients (18.5%) experienced bladder recurrence. An older age, a higher path-
ological stage, positive surgical margins, and distant metastases were significant predictors of
overall survival (p Z 0.031, p Z 0.001, p Z 0.001, and p Z 0.011, respectively). Meanwhile,
previous bladder instillation and positive surgical margins were significant predictors of
bladder recurrence (p Z 0.026 and p Z 0.027, respectively). The rate of consecutive distant
metastases (33.3%) was almost twice the rate of bladder recurrence (18.5%), and six patients
developed consecutive distant metastases without first experiencing bladder recurrence. In
patients who received a simple partial cystectomy as an alternative treatment, previous
bladder instillation and positive surgical margins were significant predictors of bladder recur-
rence. Patients with an older age, positive surgical margins, and consecutive distant metasta-
ses had worse overall survival. Partial cystectomy with routine lymph node dissection may be a
better option for achieving favorable long-term outcomes.eclare no conflicts of interest.
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Urothelial carcinoma of the urinary bladder is strongly
associated with environmental factors and age. The inci-
dence and prevalence rates increase with age, peaking in
the 8th decade of life [1,2]. In the United States in 2007,
bladder urothelial carcinoma accounted for 7% of all can-
cers [1]. In addition to its high prevalence, bladder cancer
is fatal, accounting for 3% of all cancer deaths in the United
States in 2007. However, due to advancements in treatment
strategies and modalities, bladder cancer mortality
decreased by 5% between 1990 and 2004, despite a
continuous rise in the incidence of the disease [1].
Radical cystectomy is one of the main treatment options
for localized muscle invasive bladder urothelial carcinoma
and select nonmuscle invasive disease. However, along with
cancer control, radical cystectomy also results in some
degree of reduction in the quality of life; it impacts
continence, body image, and potency. These consequences
make bladder preservation during treatment an important
goal, for both patients and surgeons, in advanced bladder
cancer cases.
A partial cystectomy with pelvic lymph node dissection
can be reserved for select patients with a solitary lesion for
whom radical cystectomy is otherwise contraindicated and
a sufficient margin can be obtained. Some previous studies
noted the comparable prognosis of radical cystectomy and
partial cystectomy with adequate patient selection [3,4].
In this study, we analyzed patients who underwent
simple partial cystectomy without pelvic lymph node
dissection with the aim of identifying predictors of bladder
cancer recurrence and overall survival in this population.
Materials and methods
Twenty-seven patients who underwent a simple partial
cystectomy without pelvic lymph node dissection at our
hospital between March 2000 and September 2013 were
included in this study. These patients were diagnosed with
bladder urothelial carcinoma, and the diagnosis was
confirmed by transurethral resection of bladder tumors
(TUR-BT). All patients met the criteria for radical cys-
tectomy, but underwent simple partial cystectomy due to
medical considerations or on the basis of their own deci-
sion. Computed tomography scans and bone scans were
performed for staging before the operation. The absence of
lymph node and distant metastases was determined by
imaging studies. All bladder lesions were solitary with
adequate resection margins of at least 1 cm. No neo-
adjuvant chemotherapy or radiation therapy was adminis-
tered. Adjuvant chemotherapy or radiation therapy was
prescribed according to the pathological results, i.e., if at
least one of the following criteria was met: pathological
Stage T3 or Stage T4 disease, or positive surgical margins.The prognosis analysis was based on overall survival and
recurrence-free survival. Parameters included general pa-
tient characteristics (sex, age, body mass index), tumor
factors (pathological T stage, tumor histology, tumor size,
and pathological grade), surgical factors (American Society
of Anesthesiologists score and surgical margins), and pre-
vious bladder tumor conditions (previous intravesical
instillation including chemotherapy or bacillus Calmette-
Guerin (BCG) instillation and previous TUR-BT history and
number). Here, the TUR-BT history did not refer to TUR-BT
for the same bladder tumor, but to any previous superficial
bladder tumor history for which bladder preservation
therapy with TUR-BT was performed.
Statistical analyses were performed using SPSS version
17 software (Linkou, Taoyuan, Taiwan). Statistical methods
included frequency descriptions and a Kaplan-Meier sur-
vival analysis. The study was approved by the Institutional
Review Board.Results
Patient characteristics are listed in Table 1. The mean age
of patients who underwent partial cystectomy was
70.6 years (range 49e90 years). The mean follow-up time
after partial cystectomy was 39.0 months. The patients
were predominantly male, with a male to female ratio of
5.8.
Overall, 63% (17) of patients had pathological Stage T1
or Stage T2 disease, while Stage T3 and Stage T4 disease
accounted for 33.3% (9) and 3.7% (1) of cases, respectively.
The most common tumor histology was infiltrating carci-
noma (74%); other histologies included papillary (14.8%),
sarcomatoid (7.4%), and poorly differentiated types (3.7%).
In terms of pathological grade, high-grade tumors accoun-
ted for 88.9% of all cases.
Fourteen (51.9%) patients had superficial bladder tumors
for which they had previously received TUR-BT. Among
these 14 patients, 11 (40.7%) had undergone TUR-BT once
and three had received TUR-BT at least twice. Previous
intravesical therapies including epirubicin, mitomycin, and
BCG instillation were prescribed according to individual
status in keeping with the National Comprehensive Cancer
Network guidelines [5]. Pathological specimen examination
showed that four (14.8%) patients had residual cancer at
the surgical margin and 23 (85.2%) patients had clear sur-
gical margins.
During a mean follow up of 39.0  39.0 months, five
(18.5%) patients experienced tumor recurrence in the
bladder, nine (33.3%) patients developed distant metastasis
postsurgically, and 10 (37%) patients died. Results of the
univariate analysis performed using KaplaneMeier survival
curves for overall survival are shown in Table 2. Significant
predictors of overall survival in patients who received
partial cystectomy were: age > 70 years, a higher
Table 1 Patient characteristics.
Mean patient age (y) 70.6  10.7 (49e90)
Mean follow-up time (mo) 39.0  39 (3.13e148.4)
Body mass index (kg/m2) 24.4  2.88 (20.7e34.4)
Sex
Male 23 (85.2)
Female 4 (14.8)
Pathological T stage
1 10 (37.0)
2 7 (25.9)
3 9 (33.3)
4 1 (3.7)
Mean tumor size (cm) 2.97  1.7
Pathological pattern
Infiltrating 20 (74)
Papillary 4 (14.8)
Sarcomatoid 2 (7.4)
Poorly differentiated 1 (3.7)
Pathological grade
High 24 (88.9)
Low 3 (11.1)
ASA score
1 1 (3.7)
2 13 (48.1)
3 13 (48.1)
Previous TUR-BT
No 13 (48.1)
Yes 14 (51.9)
Previous number of TUR-BTs
0 13 (48.1)
1 11 (40.7)
2 1 (3.7)
3 1 (3.7)
4 1 (3.7)
Previous intravesical instillation
Epirubicin 2 (7.4)
Mitomycin 1 (3.7)
BCG 1 (3.7)
Surgical margin
Negative 23 (85.2)
Positive 4 (14.8)
Bladder recurrence
No 22 (81.5)
Yes 5 (18.5)
Distant metastasis
No 18 (66.7)
Yes 9 (33.3)
Data are presented as mean  SD (range) or n (%).
ASA score Z American Society of Anesthesiologists score;
BCG Z bacillus CalmetteeGuerin; SD Z standard deviation;
TUR-BT Z transurethral resection of bladder tumors.
Table 2 Univariate analysis of predictors of overall
survival.
No. of cases Mean survival
time (mo)
No. of
deaths
p
Sex
Female 4 27.8  10 2 0.121
Male 23 88.0  16 8
Age (y)*
< 70 13 118.7  18 2 0.031*
 70 14 47.2  13 8
Body mass index (kg/m2)
 24 12 94.7  19.9 4 0.670
> 24 13 57.1  12.3 4
Pathological T stage*
1 10 94.8  11 2 0.001*
2 7 26.0  7 4
3 9 91.1  25 3
4 1 4.6 1
Tumor size (cm)
< 2 6 57.8  10 1 0.870
 2 and < 4 12 65.6  15 5
 4 9 81.9  23 4
Histology
Papillary 4 63.8  12 3 0.539
Infiltrating 20 93.5  18 6
Others
(sarcomatoid and
poorly
differentiated)
3 82.0  15 1
Pathological grade
Low 3 88.3  20 1 0.312
High 24 75.3  16 9
ASA score
1 1 0 0.202
2 13 103.2  18 4
3 13 33.2  5.4 6
Previous TUR-BT
No 13 67.2  15 5 0.875
Yes 14 82.4  20 5
Number of
previous TUR-BTs
0 13 67.2  15 5 0.440
1 11 89.4  20 4
 2 3 16.1  15 1
Previous intravesical instillation
No 24 10 0.582
Yes 3 0
Surgical margin*
Negative 23 93.0  16 7 0.001*
Positive 4 16.5  8 3
Bladder recurrence
No 22 92.4  16 7 0.154
Yes 5 44.9  23 3
Distant metastasis*
No 18 102.2  18 4 0.011*
Yes 9 37.9  14 6
*p < 0.05.
ASA score Z American Society of Anesthesiologists score; TUR-
BT Z transurethral resection of bladder tumors.
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consecutive distant metastases (p Z 0.031, p Z 0.001,
p Z 0.001, and p Z 0.011, respectively).
Results of the univariate analysis of recurrent-free sur-
vival are shown in Table 3. Previous bladder intravesical
instillation and positive surgical margins were significant
predictors of bladder tumor recurrence (p Z 0.026 and
Table 3 Univariate analysis of predictors of bladder
recurrence-free survival.
No. of cases Mean
recurrence-free
time (mo)
No. of
deaths
p
Sex
Female 4 0 0.346
Male 23 5
Age (y)
< 70 13 126.2 2 0.606
 70 14 87.7 3
Body mass index (kg/m2)
 24 12 124.4 2 0.637
> 24 13 69.4 3
Pathological T stage
1 10 90.6 2 0.956
2 7 34.96 1
3 9 114.1 2
4 1 0
Tumor size (cm)
< 2 6 57.8 1 0.956
 2 and < 4 12 93.6 2
 4 cm 9 116.3 2
Histology
Papillary 4 68.3 1 0.539
Infiltrating 20 118.7 4
Others
(sarcomatoid
and poorly
differentiated)
3 0
Pathological grade
Low 3 0 0.393
High 24 5
ASA score
1 1 0 0.774
2 13 3
3 13 2
Previous TUR-BT
No 13 95.1 2 0.700
Yes 14 116.5 3
No. of previous TUR-BTs
0 13 95.1 2 0.078
1 11 135.2 1
 2 3 8.4 2
Previous
intravesical
instillation*
No 24 129.7 10 0.026*
Yes 3 8.1 0
Surgical margin*
Negative 23 129.5 3 0.027*
Positive 4 5.3 2
*p < 0.05.
ASA score Z American Society of Anesthesiologists score; TUR-
BT Z transurethral resection of bladder tumors.
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than two previous TUR-BTs appeared more likely to have
tumor recurrence, although this was not statistically sig-
nificant (p Z 0.078).Discussion
Ninety percent of urinary bladder cancers are urothelial
cell carcinomas [6], with muscle invasive disease account-
ing for 80% of urothelial tumors at initial presentation.
Radical cystectomy remains the most frequently utilized
surgical intervention for clinical Stage T2 and Stage T3
bladder urothelial carcinoma without lymph node or distant
metastases. Cystectomy may also be indicated for select
superficial bladder tumors, for example, recurrent pT1
high-grade tumors.
For patients in whom radical cystectomy is indicated,
but who wish to preserve the urinary bladder, alternative
treatments include radical TUR-BT, partial cystectomy, and
neoadjuvant concomitant chemoradiotherapy. Partial cys-
tectomy plays a role in select patients with appropriately
located solitary tumors and resectable margins. A standard
partial cystectomy should include bilateral pelvic lymph
node dissection to confirm lymph node stage.
Previous studies have reported on prognosis with standard
partial cystectomy, along with predictors of survival or
recurrence. Holzbeierlein and colleagues [3] reviewed the
cases of 58 select patients who underwent partial cystectomy
with pelvic lymph node dissection for bladder urothelial car-
cinoma and were followed up for 33 months. They reported
that partial cystectomywith pelvic lymphnode dissection can
result in comparable outcomes in specifically selected pa-
tients. In addition, concomitant carcinoma in situ and lymph
node metastasis were found to be predictors of advanced
recurrence. Smaldone and colleagues [4] reviewed the cases
of 25patientswithprimary solitaryT2orhigh-gradeT1 tumors
who received preoperative radiation for 5 days and a single
dose of intraoperative intravesical chemotherapy followedby
partial cystectomy with pelvic lymph node dissection. Over a
follow-up period of 11 years, the cancer-specific 5-year sur-
vival was 84%. To the best of our knowledge, the role and
prognosis of simple partial cystectomy have not been dis-
cussed in previous studies.
In this study, we aimed to identify prognostic predictors
for patients who underwent a simple partial cystectomy.
During a mean follow-up time of 39 months, the bladder
tumor recurrence rate was 18.5%, with an overall survival
rate of 63%. The significant predictors of poor overall sur-
vival were: age > 70 years, a higher T stage, positive sur-
gical margins, and consecutive distant metastases. These
predictors were similar to the prognostic factors of patients
who underwent a radical cystectomy [7e9]. In addition,
previous intravesical bladder instillation and positive sur-
gical margins were significant predictors of bladder tumor
recurrence. This can be explained by the fact that patients
for whom intravesical instillation was indicated had a T1
high-grade tumor, coexisting carcinoma in situ, or a
recurrent bladder tumor. These patients are at high risk for
bladder tumor recurrence after partial cystectomy. Pa-
tients with positive surgical margins after a partial cys-
tectomy also had a high probability of bladder tumor
recurrence despite adjuvant chemotherapy or radiation
therapy. Thus, a more aggressive follow up is important in
these patients. Although not significant, patients with a
history of multiple previous TUR-BTs (>2) were more likely
to have bladder tumor recurrence (p Z 0.078).
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consecutive distant metastases (33.3%) was almost twice
that of recurrence in the bladder (18.5%). This rate was also
higher than that reported for another case series of partial
cystectomy with pelvic lymph node dissection [3]. Among
patients with distant metastases, six developed consecu-
tive distant metastases without first having a recurrence in
the bladder. This may be due to the high potential for
lymph node metastasis, even though preoperative
computed tomography scans were negative for lymph node
metastasis. In patients with potential lymph node metas-
tases, the bilateral pelvic lymph nodes played an important
role, not only in the staging diagnosis, but also in terms of
the survival benefit, because consecutive distant metasta-
ses had a significant effect on overall survival.
Conclusion
For patients who underwent simple partial cystectomy as
an alternative treatment, previous bladder instillation (due
to previous high-grade or carcinoma in situ tumors) and
positive surgical margins were significant predictors of
bladder tumor recurrence. Patients aged > 70 years, and
those with positive surgical margins and consecutive distant
metastases, had worse overall survival.
With adequate patient selection and proper post-
operative follow up, simple partial cystectomy without
pelvic lymph node dissection could provide a favorable
prognosis for local bladder tumor recurrence. However, the
lymph node or distant metastasis rate appeared relatively
higher in our patients than in patients who received partial
cystectomy with pelvic lymph node dissection in other re-
ported case series. A possible reason for the variation in
results may be that potential lymph node metastases were
missed on preoperative images. For patients who are eligiblefor partial cystectomy, simultaneous lymph node dissection
may result in more favorable long-term outcomes in terms of
overall survival or distant metastases, even in those without
suspected lymph node metastasis.References
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